Organigram (OGI.V) executives released the bare minimum information in a news release an hour ago, announcing their earlier confirmed product recall, in which non-organic, banned chemicals were found in their products, has been expanded.

Literally, that’s all they said. Oh, they also claimed you should look to Health Canada’s website for more information. So I did. There’s none there.

Shortly before the last trading day of 2016, leading into a holiday weekend, Organigram released the initial news that a recall had taken place. They didn’t mention what the substance was that had been found, and said they had no idea why it was there.

They also said that five minutes before the close of trading leading into a three-day weekend. Because, naturally.

Today’s release was even less helpful to investors:

Organigram Holdings Inc. announces that it has expanded its product recall announced on December 30, 2016 to include additional product lots manufactured during 2016. The Company continues to work closely with Health Canada on this matter. For more information, visit Health Canada’s website. Organigram’s client service department is directly notifying all clients affected by the recall.

That’s it. There’s nothing more to see, people. Move along.

In fact, the news was so sparse, if you do a search for the story on Twitter, you’ll see every news organization mention features the same word: BRIEF


Frankly, it appears Organigram CEO Denis Arsenault couldn’t run a choko vine over a shithouse, as we used to say in Australia. His organic certification, which his website boasts means:

organigram-organic… must surely be in peril. The stock has been dragging at a time others are putting big runs on the board, and the approach used to inform the market – you know, you guys who invest in the company – about material issues is SERIOUSLY suspect.

No good CEO releases big news five minutes before a three day weekend. No good CEO puts out a one line news release with no detail on which strains are affected and why. No good CEO would let this happen in the first place, when your entire reason for being in business is supposed to be how much better organic weed is.

It’s time for Organigram’s board to move Arsenault aside, if he won’t go willingly. Then again, he’s padded himself with so many shares and options over the years, he might be tough to dislodge.

— Chris Parry

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Health Canada
Medical marijuana
product recall
0 0 votes
Article Rating
Notify of
1 Comment
Newest Most Voted
Inline Feedbacks
View all comments

Buyout target while sp under pressure? Mentioned in this interview at the end… thoughts on Chris Damas’ comments? I’ve come across investors using the drops and fear as opportunities and even hoping it will drop again lower to load up. Someone still sees value… tbd how plays out and if more recalls to come.